Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway (Q26800894)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway	scientific article

Statements

scholarly article

0 references

9 references

21 March 2019

20 June 2019

6 August 2019

19 September 2019

7 October 2019

8 September 2020

12 November 2020

17 December 2020

22 August 2022

Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway (English)

0 references

1 reference

17 December 2020

steatohepatitis

0 references

metabolic dysfunction–associated steatotic liver disease

7 references

21 March 2019

20 June 2019

6 August 2019

19 September 2019

7 October 2019

8 September 2020

12 November 2020

pharmaceutical preparation

1 reference

6 August 2019

biomedical investigative technique

1 reference

19 September 2019

human digestive system

1 reference

7 October 2019

investigational drugs

1 reference

8 September 2020

gastrointestinal agent

1 reference

12 November 2020

non-alcoholic steatohepatitis

1 reference

based on heuristic

inferred from title

Claudia Filozof

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201461%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

author name string

Barry J Goldstein

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201461%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Richard N Williams

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201461%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Arun Sanyal

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201461%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

language of work or name

0 references

publication date

August 2015

0 references

1 August 2015

9 references

21 March 2019

20 June 2019

6 August 2019

19 September 2019

7 October 2019

8 September 2020

12 November 2020

17 December 2020

22 August 2022

10 references

21 March 2019

20 June 2019

6 August 2019

19 September 2019

7 October 2019

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201461%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

8 September 2020

12 November 2020

17 December 2020

22 August 2022

75

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201461%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201461%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

1373-1392

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201461%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

copyright license

Creative Commons Attribution-NonCommercial

9 references

21 March 2019

20 June 2019

6 August 2019

19 September 2019

7 October 2019

8 September 2020

12 November 2020

17 December 2020

22 August 2022

on focus list of Wikimedia project

0 references

https://scigraph.springernature.com/pub.10.1007/s40265-015-0437-3

0 references

Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

7 April 2017

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

7 April 2017

Bariatric surgery for non-alcoholic steatohepatitis in obese patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

7 April 2017

Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

7 April 2017

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

7 April 2017

Nonalcoholic fatty liver disease: a feature of the metabolic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

7 April 2017

Liver fibrosis in overweight patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

7 April 2017

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

7 April 2017

The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

7 April 2017

Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

7 April 2017

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

7 April 2017

Steatohepatitis: a tale of two "hits"?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

7 April 2017

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

7 April 2017

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

7 April 2017

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

7 April 2017

Long-term follow-up of patients with NAFLD and elevated liver enzymes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

7 April 2017

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

7 April 2017

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

7 April 2017

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

7 April 2017

From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Determining the association between adipokine expression in multiple tissues and phenotypic features of non-alcoholic fatty liver disease in obesity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Serum cytokeratin 18 fragment level as a noninvasive biomarker for non-alcoholic fatty liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Bariatric surgery and non-alcoholic Fatty liver disease: current and potential future treatments

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Cannabinoid signaling and liver therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Nonalcoholic fatty liver disease: current issues and novel treatment approaches

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Assessing the drinking status of liver transplant patients with alcoholic liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Nonalcoholic fatty liver disease (NAFLD): is it really a serious condition?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Diagnosis and evaluation of nonalcoholic fatty liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Endpoints and clinical trial design for nonalcoholic steatohepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

An apoptosis panel for nonalcoholic steatohepatitis diagnosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Nonalcoholic fatty liver disease in type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Nonalcoholic fatty liver disease and cardiovascular risk

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Histological assessment of non-alcoholic fatty liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Weight loss as a treatment for nonalcoholic fatty liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Assessment of the agreement between wedge hepatic vein pressure and portal vein pressure in cirrhotic patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Fatty infiltration of liver in hyperlipidemic patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 September 2017

Catalyzing the Critical Path Initiative: FDA's progress in drug development activities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

31 May 2018

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

31 May 2018

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

31 May 2018

Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

31 May 2018

Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

31 May 2018

Selection and outcome of living donors for adult to adult right lobe transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

31 May 2018

Hepatic effects of dietary weight loss in morbidly obese subjects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

31 May 2018

NASH: A global health problem

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0437-3

21 January 2018

Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0437-3

21 January 2018

Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0437-3

21 January 2018

The histologic spectrum of liver disease in African-American, non-Hispanic white, and Hispanic obesity surgery patients

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0437-3

21 January 2018

Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0437-3

21 January 2018

Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0437-3

21 January 2018

Long-term follow-up of patients with nonalcoholic fatty liver

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0437-3

21 January 2018

Upper normal threshold of serum alanine aminotransferase in identifying individuals at risk for chronic liver disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0437-3

21 January 2018

A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0437-3

21 January 2018

Magnetic resonance elastography for the noninvasive staging of liver fibrosis.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0437-3

21 January 2018

Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0437-3

21 January 2018

Therapeutic effects of restricted diet and exercise in obese patients with fatty liver.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0437-3

21 January 2018

Dietary fat content modifies liver fat in overweight nondiabetic subjects.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0437-3

21 January 2018

Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0437-3

21 January 2018

Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0437-3

21 January 2018

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0437-3

21 January 2018

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0437-3

21 January 2018

Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0437-3

21 January 2018

Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0437-3

21 January 2018

Could inflammatory markers help diagnose nonalcoholic steatohepatitis?

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0437-3

21 January 2018

Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0437-3

21 January 2018

Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: Results of a US national survey in three ethnic groups

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0437-3

21 January 2018

Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0437-3

21 January 2018

No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 November 2018

TNF-α messenger ribonucleic acid (mRNA) in patients with nonalcoholic steatohepatitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 November 2018

Predictive factors for nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 November 2018

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 November 2018

Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4532706

28 November 2018

Accelerated access to innovative medicines for patients in need

1 reference

https://pubmed.ncbi.nlm.nih.gov/26201461

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High Visceral Fat Mass and High Liver Fat Are Associated with Resistance to Lifestyle Intervention*

1 reference

https://pubmed.ncbi.nlm.nih.gov/26201461

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

1 reference

https://pubmed.ncbi.nlm.nih.gov/26201461

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/26201461

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/26201461

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26201461

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/26201461

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years

1 reference

https://pubmed.ncbi.nlm.nih.gov/26201461

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

1 reference

https://pubmed.ncbi.nlm.nih.gov/26201461

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26201461

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/26201461

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Transient elastography with a new probe for obese patients for non-invasive staging of non-alcoholic steatohepatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26201461

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40265-015-0437-3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201461%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Dimensions Publication ID

0 references

release_3nchtm45wfcejbr26nvvscypuu

0 references

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201461%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201461%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q26800894&oldid=1988615059"